[go: up one dir, main page]

MX2018010815A - Composiciones y metodos para tratar artritis reumatoide. - Google Patents

Composiciones y metodos para tratar artritis reumatoide.

Info

Publication number
MX2018010815A
MX2018010815A MX2018010815A MX2018010815A MX2018010815A MX 2018010815 A MX2018010815 A MX 2018010815A MX 2018010815 A MX2018010815 A MX 2018010815A MX 2018010815 A MX2018010815 A MX 2018010815A MX 2018010815 A MX2018010815 A MX 2018010815A
Authority
MX
Mexico
Prior art keywords
treat
compositions
methods
reumatoid arthritis
arthritis
Prior art date
Application number
MX2018010815A
Other languages
English (en)
Inventor
Graham Neil
Lin Yong
VAN HOOGSTRATEN Hubert
Patel Rahul
Bauer Deborah
Boddy Alexander
Parrino Janie
Van Adelsberg Janet
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2018010815A publication Critical patent/MX2018010815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de un anticuerpo anti-receptor de IL6 en monoterapia para tratar la artritis reumatoide y para mejorar la función física y la calidad de vida de un sujeto que padece artritis reumatoide.
MX2018010815A 2016-03-07 2017-03-07 Composiciones y metodos para tratar artritis reumatoide. MX2018010815A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2018010815A true MX2018010815A (es) 2019-01-10

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010815A MX2018010815A (es) 2016-03-07 2017-03-07 Composiciones y metodos para tratar artritis reumatoide.
MX2023014841A MX2023014841A (es) 2016-03-07 2018-09-07 Composiciones para tratar artritis reumatoide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023014841A MX2023014841A (es) 2016-03-07 2018-09-07 Composiciones para tratar artritis reumatoide.

Country Status (18)

Country Link
US (1) US20190100585A1 (es)
EP (1) EP3426295A1 (es)
JP (2) JP7166925B2 (es)
KR (2) KR20180114955A (es)
CN (1) CN109069642A (es)
AU (2) AU2017229364A1 (es)
BR (1) BR112018067851A2 (es)
CA (1) CA3016880A1 (es)
CL (1) CL2018002559A1 (es)
CR (1) CR20180465A (es)
EA (1) EA201892005A1 (es)
IL (2) IL308539A (es)
MX (2) MX2018010815A (es)
PH (1) PH12018501894A1 (es)
SG (2) SG10202012182YA (es)
TN (1) TN2018000312A1 (es)
TW (3) TWI819435B (es)
WO (1) WO2017155990A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AU2018374232A1 (en) * 2017-11-30 2020-07-23 Bio-Thera Solutions, Ltd. Liquid preparation of humanized antibody for treating IL-6-related disease
MA53481A (fr) * 2018-08-29 2021-07-07 Regeneron Pharma Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
SG11202107735SA (en) * 2019-01-31 2021-08-30 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
US12440561B2 (en) 2019-04-24 2025-10-14 Sanofi Biotechnology Method of diagnosis and treatment of rheumatoid arthritis
BR112021024445A2 (pt) 2019-06-04 2022-02-15 Regeneron Pharma Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CA2930615C (en) * 2013-11-22 2023-04-04 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
WO2017155990A1 (en) 2017-09-14
TW202419103A (zh) 2024-05-16
US20190100585A1 (en) 2019-04-04
EA201892005A1 (ru) 2019-02-28
AU2017229364A1 (en) 2018-10-25
IL261515B2 (en) 2024-04-01
TN2018000312A1 (en) 2020-01-16
SG11201807614SA (en) 2018-10-30
BR112018067851A2 (pt) 2019-02-05
JP7166925B2 (ja) 2022-11-08
JP2023011711A (ja) 2023-01-24
AU2024203011A1 (en) 2024-07-11
TWI747885B (zh) 2021-12-01
NZ746988A (en) 2023-10-27
MX2023014841A (es) 2024-01-15
IL308539A (en) 2024-01-01
KR20230093522A (ko) 2023-06-27
IL261515B1 (en) 2023-12-01
CL2018002559A1 (es) 2019-03-01
JP2019507775A (ja) 2019-03-22
TW201808993A (zh) 2018-03-16
IL261515A (en) 2018-10-31
TW202239767A (zh) 2022-10-16
CN109069642A (zh) 2018-12-21
SG10202012182YA (en) 2021-01-28
KR20180114955A (ko) 2018-10-19
EP3426295A1 (en) 2019-01-16
CA3016880A1 (en) 2017-09-14
CR20180465A (es) 2019-03-04
TWI819435B (zh) 2023-10-21
JP7745529B2 (ja) 2025-09-29
PH12018501894A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
MX2020012064A (es) Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CR20160314A (es) Anticuerpos anti-cd3 y metodos de uso
MX2023005881A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
AR081750A1 (es) Anticuerpos anti-cd40
MX2016012188A (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
CO2021011352A2 (es) Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopática